# Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19

> **NCT04428801** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Celltex Therapeutics Corporation** · enrollment: 200 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** autologous adipose-derived stem cells

## Key facts

- **NCT ID:** NCT04428801
- **Lead sponsor:** Celltex Therapeutics Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-09
- **Primary completion:** 2024-09
- **Final completion:** 2026-09
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2023-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04428801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04428801, "Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04428801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*